2022
T066: Treatment and sex‐specific exposure‐based risk‐stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study
Dinan M, Stratton K, Leisenring W, Yasui Y, Chow E, Tonorezos E, Moskowitz C, Yeh J, Noyd D, Armstrong G, Oeffinger K. T066: Treatment and sex‐specific exposure‐based risk‐stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study. HemaSphere 2022, 6: 31-31. PMCID: PMC9642057, DOI: 10.1097/01.hs9.0000890832.67877.a2.Peer-Reviewed Original ResearchChildhood Cancer Survivor StudyChildhood Hodgkin lymphomaCancer Survivor StudyCare of survivorsHodgkin's lymphomaSurvivor StudyLymphomaSurvivorsCareTreatment exposure-based risk-stratification for care of survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.
Dinan M, Stratton K, Leisenring W, Yasui Y, Chow E, Moskowitz C, Yeh J, Noyd D, Armstrong G, Oeffinger K. Treatment exposure-based risk-stratification for care of survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Journal Of Clinical Oncology 2022, 40: 10056-10056. DOI: 10.1200/jco.2022.40.16_suppl.10056.Peer-Reviewed Original ResearchChildhood Cancer Survivor StudyHigh-risk groupHigh-risk survivorsCancer Survivor StudyRisk groupsGrade 3Hazard ratioRisk survivorsAge 20Cumulative incidenceChronic conditionsSurvivor StudyChildhood cancerAge 35Treatment exposureLow-risk survivorsFive-year survivorsHigh-risk patientsRisk stratification algorithmConfidence intervalsProportional hazards modelLong-term surveillanceCare of survivorsLate mortalityPrimary endpoint
2021
The Evolution of Children's Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity
Lo A, Liu A, Liu Q, Yasui Y, Castellino S, Kelly K, Herrera A, Friedberg J, Friedman D, Schwartz C, Bergeron-Gravel S, Dama H, Roberts K, Constine L, Hodgson D. The Evolution of Children's Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity. Blood 2021, 138: 881. DOI: 10.1182/blood-2021-147678.Peer-Reviewed Original ResearchInvolved site radiotherapyCardiac radiation doseInvolved-field radiotherapyChildhood Cancer Survivor StudyPositron emission tomographyMediastinal radiotherapyChildren's Oncology GroupDoxorubicin doseCumulative incidenceCardiac toxicityCardiac diseaseRT useCardiac riskCardiac disease riskBulk diseaseOncology GroupLymphoma trialsTrial protocolRadiation doseLong-term cardiac riskDisease riskCumulative doxorubicin doseImpact of nivolumabLate cardiac toxicityMean heart doseLongitudinal Evaluation of Neuromuscular Dysfunction in Long-term Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study
Rodwin RL, Chen Y, Yasui Y, Leisenring WM, Gibson TM, Nathan PC, Howell RM, Krull KR, Mohrmann C, Hayashi RJ, Chow EJ, Oeffinger KC, Armstrong GT, Ness KK, Kadan-Lottick NS. Longitudinal Evaluation of Neuromuscular Dysfunction in Long-term Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study. Cancer Epidemiology Biomarkers & Prevention 2021, 30: 1536-1545. PMID: 34099519, PMCID: PMC8523186, DOI: 10.1158/1055-9965.epi-21-0154.Peer-Reviewed Original ResearchConceptsChildhood Cancer Survivor StudyChildhood cancer survivorsCancer Survivor StudyNeuromuscular dysfunctionCumulative incidenceSpinal radiotherapyYears postdiagnosisCancer survivorsPrevalence ratiosSurvivor StudyCentral nervous system tumorsLong-term survivorsNervous system tumorsLater obesityRadiotherapy doseCNS tumorsSystem tumorsChildhood cancerMultivariable modelPlatinum exposureDysfunctionLongitudinal evaluationSurvivorsPrevalenceRadiation exposure
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply